The impact of modern therapeutic approaches in the treatment of chronic obstructive pulmonary disease on patients' quality of life

Authors

  • Mesedu Musaeva Dagestan State Medical University, 1, pr. Shamilya, Makhachkala, 367000, Russian Federation
  • Elena Gazashvili Kuban State Medical University, 4, ul. Sedina, Krasnodar, 350063, Russian Federation
  • Yana Rotarash Kaluga State University named after K. E. Tsiolkovsky, 26, ul. Stepana Razina, Kaluga, 248023, Russian Federation
  • Aminat Radzhabova Stavropol State Medical University, 310, ul. Mira, Stavropol, 355017, Russian Federation
  • Nise Ismailova Astrakhan State Medical University, 121, ul. Bakinskaya, Astrakhan, 414056, Russian Federation

DOI:

https://doi.org/10.21638/spbu11.2024.402

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases, significantly reducing patients' quality of life. This article reviews current therapeutic approaches, such as pharmacological therapy using combinations of long-acting beta-agonists (LABA) and inhaled corticosteroids (ICS), as well as pulmonary rehabilitation. Pharmacotherapy with LABA has proven effective in improving lung function and reducing shortness of breath. Despite the risk of pneumonia, ICS continues to be used in combination with bronchodilators in patients with frequent exacerbations, showing its effectiveness. Rehabilitation programs not only increase physical endurance but also reduce the frequency of hospitalizations. This paper analyzes the results of recent clinical studies demonstrating the effectiveness of these methods in reducing the frequency of exacerbations and improving lung function. Special attention is given to the prospects of using biological drugs and gene therapy, which are in the clinical trial stage and have the potential to significantly improve patient outcomes. Despite these achievements, there remain unresolved questions regarding long-term safety and the selection of optimal therapeutic strategies for various patient phenotypes.

Keywords:

COPD, bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, biological drugs, gene therapy

Downloads

Download data is not yet available.
 

References


References

Safiri S., Carson-Chahhoud K., Noori M., Nejadghaderi S. A., Sullman M. J. M., Ahmadian Heris J.,Ansarin K., Mansournia M. A., Collins G. S., Kolahi A. A., Kaufman J. S. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990–2019: Results from the Global Burden of Disease Study 2019. BMJ, 2021, vol. 378, pp. e069679.

Zou J., Sun T., Song X., Liu Y., Lei F., Chen M. M., Chen Z., Zhang P., Ji Y., Zhang X., She Z., Cai J., Luo Y., Wang P., Li H. Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: A systematic analysis of GBD 2019 data. Respiratory Research, 2022, vol. 23, no. 1, pp. 90. https://doi.org/10.1186/s12931-022-02011-y

Valipour A., Aisanov Z., Avdeev S., Koblizek V., Kocan I., Kopitovic I., Lupkovics G., Man M., Bukovskis M., Tudoric N., Vukoja M., Naumnik W., Yanev N. Recommendations for COPD management in Central and Eastern Europe. Expert Review of Respiratory Medicine, 2022, vol. 16, no. 2, pp. 221–234. https://doi.org/10.1080/17476348.2021.2023498

Kahnert K., Jörres R. A., Behr J., Welte T. The diagnosis and treatment of COPD and its comorbidities. Deutsches Ärzteblatt International, 2023, vol. 120, no. 25, pp. 434–444. https://doi.org/10.3238/arztebl.m2023.027

Wedzicha J. A., Banerji D., Chapman K. R., Vestbo J., Roche N., Ayers R., Thach C., Fogel R., Patalano F., Vogelmeier C. FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. The New England Journal of Medicine, 2016, vol. 374, no. 23, pp. 2222–2234. https://doi.org/10.1056/NEJMoa1516385

Vogelmeier C. F., Worth H., Buhl R., Criée C. P., Gückel E., Kardos P. Impact of switching from triple therapy to dual bronchodilation in COPD: The DACCORD ‘real world’ study. Respiratory Research, 2022, vol. 23, no. 1, pp. 109. https://doi.org/10.1186/s12931-022-02037-2

Suissa S. Triple therapy in COPD: Understanding the data. ERJ Open Research, 2023, vol. 9, no. 1,pp. 00615–2022. https://doi.org/10.1183/23120541.00615-2022

Almagro P., Martinez-Camblor P., Soriano J. B. Inhaled corticosteroids and pneumonia mortality in COPD patients. European Respiratory Journal, 2019, vol. 54, no. 3, pp. 1901035. https://doi.org/10.1183/13993003.01035-2019

Lipson D., Barnhart F., Brealey N., Brooks J., Criner G. J., Day N. C., Dransfield M. T., Halpin D. M. G.,Han M. K., Jones C. E., Kilbride S., Lange P., Lomas D. A., Martinez F. J., Singh D., Tabberer M.,Wise R. A., Pascoe S. J. IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. The New England Journal of Medicine, 2018, vol. 378, no. 18, pp. 1671–1680. https://doi.org/10.1056/NEJMoa1713901

Singh D., Emirova A., Francisco C., Santoro D., Govoni M., Nandeuil M. A. Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: The PIONEER study. Respiratory Research, 2020, vol. 21, no. 1, pp. 246. https://doi.org/10.1186/s12931-020-01512-y

Roque A., Taborda-Barata L., Cruz Á.A., Viegi G., Maricoto T. COPD treatment — a conceptual review based on critical endpoints. Pulmonology, 2023, vol. 29, no. 5, pp. 410–420. https://doi.org/10.1016/j.pulmoe.2023.02.015

Li Y., Ji Z., Wang Y., Li X., Xie Y. Breathing exercises in the treatment of COPD: An overview of systematic reviews. International Journal of Chronic Obstructive Pulmonary Disease, 2022, vol. 17, pp. 3075–3085. https://doi.org/10.2147/COPD. S385855

Turégano-Yedro M., Trillo-Calvo E., Navarro I. Ros F., Maya-Viejo J. D., González Villaescusa C.,Echave Sustaeta J. M., Doña E., Alcázar Navarrete B. Inhaler adherence in COPD: A crucial step towards the correct treatment. International Journal of Chronic Obstructive Pulmonary Disease, 2023,vol. 18, pp. 2887–2893. https://doi.org/10.2147/COPD.S431829

Ferri S., Paoletti G., Pelaia C., Heffler E., Canonica G. W., Puggioni F. COPD and biologic treatment:State of the art. Current Opinion in Allergy and Clinical Immunology, 2023, vol. 23, no. 4, pp. 309–318.https://doi.org/10.1097/ACI.0000000000000920

Donovan T., Milan S. J., Wang R., Banchoff E., Bradley P., Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2020, vol. 12, pp. CD013432. https://doi.org/10.1002/14651858.CD013432.pub2

Christine H., Johnson E. A., Wiesel S. Unleashing the power of IL-17: A promising frontier in chronic obstructive pulmonary disease (COPD) treatment. Cureus, 2024, vol. 15, no. 7, e41977 p. https://doi.org/10.7759/cureus.41977

Uwagboe I., Adcock I. M., Lo Bello F., Caramori G., Mumby S. New drugs under development for COPD. Minerva Medica, 2022, vol. 113, no. 3, pp. 471–496. https://doi.org/10.23736/S0026-4806.22.08024-7

Lai S., Guo Z. Stem cell therapies for chronic obstructive pulmonary disease: Mesenchymal stem cells as a promising treatment option. Stem Cell Research & Therapy, 2024, vol. 15, no. 1, 312 p. https://doi.org/10.1186/s13287-024-03940-9

Nguyen H. T., Collins P. F., Pavey T. G., Nguyen N. V., Pham T. D., Gallegos D. L. Nutritional status, dietary intake, and health-related quality of life in outpatients with COPD. International Journal of Chronic Obstructive Pulmonary Disease, 2019, vol. 14, pp. 215–226. https://doi.org/10.2147/COPD.S181322

Saka S., Gurses H. N., Bayram M. Effect of inspiratory muscle training on dyspnea-related kinesiophobia in chronic obstructive pulmonary disease: A randomized controlled trial. Complementary Therapies in Clinical Practice, 2021, vol. 44, pp. 101418. https://doi.org/10.1016/j.ctcp.2021.101418

Downloads

Published

2025-04-21

How to Cite

Musaeva , M., Gazashvili , E., Rotarash , Y., Radzhabova , A., & Ismailova , N. (2025). The impact of modern therapeutic approaches in the treatment of chronic obstructive pulmonary disease on patients’ quality of life. Vestnik of Saint Petersburg University. Medicine, 19(4), 311–322. https://doi.org/10.21638/spbu11.2024.402

Issue

Vol. 19 No. 4 (2024)

Section

Internal medicine

License

Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.